Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Acq. announced Director departure Appointed director
|
PhaseBio Pharmaceuticals Inc (PHAS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
05/19/2023 |
4
| van den Broek Richard (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 3,750 shares
@ $0 Exercised 3,750 restricted stock units
@ $0 |
|
05/19/2023 |
4
| Thorp Clay (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
05/19/2023 |
4
| Humphries William D. (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Exercised 2,538 restricted stock units
@ $0 |
|
05/19/2023 |
4
| HARRIGAN EDMUND (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
05/19/2023 |
4
| Sapir Alex (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
05/19/2023 |
4
| Loewy Caroline M (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
05/19/2023 |
4
| Hutson Nancy J (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Exercised 3,750 restricted stock units
@ $0 |
|
10/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/24/2022 |
4
| Hanson Kristopher (SVP and General Counsel) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 4,831 shares
@ $0.6813, valued at
$3.3k
|
|
05/24/2022 |
4
| Birchall Jonathan (Chief Commercial Officer) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 20,000 shares
@ $0.6813, valued at
$13.6k
|
|
05/24/2022 |
4
| Sharp John P (CFO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 6,026 shares
@ $0.6813, valued at
$4.1k
|
|
05/20/2022 |
4
| Humphries William D. (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 17,500 options to buy
@ $0.8419, valued at
$14.7k
Granted 3,750 restricted stock units
@ $0 |
|
05/20/2022 |
4
| Thorp Clay (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 17,500 options to buy
@ $0.8419, valued at
$14.7k
Granted 3,750 restricted stock units
@ $0 |
|
05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/20/2022 |
4
| Sapir Alex (Director) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 17,500 options to buy
@ $0.8419, valued at
$14.7k
Granted 3,750 restricted stock units
@ $0 |
|
05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/28/2022 |
4
| Sharp John P (CFO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 24,750 restricted stock units
@ $0 Granted 115,500 options to buy
@ $1.13, valued at
$130.5k
|
|
02/28/2022 |
4
| Burkhardt Glen (VP, Human Resources) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 18,750 restricted stock units
@ $0 Granted 87,500 options to buy
@ $1.13, valued at
$98.9k
|
|
02/28/2022 |
4
| Birchall Jonathan (Chief Commercial Officer) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 11,250 restricted stock units
@ $0 Granted 52,500 options to buy
@ $1.13, valued at
$59.3k
|
|
02/28/2022 |
4
| Lee John Sang (Chief Medical Officer) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 24,750 restricted stock units
@ $0 Granted 115,500 options to buy
@ $1.13, valued at
$130.5k
|
|
02/28/2022 |
4
| Arnold Susan Elizabeth (SVP, Technical Operations) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 18,750 restricted stock units
@ $0 Granted 87,500 options to buy
@ $1.13, valued at
$98.9k
|
|
02/28/2022 |
4
| Hanson Kristopher (VP, Head of Legal) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 18,750 restricted stock units
@ $0 Granted 87,500 options to buy
@ $1.13, valued at
$98.9k
|
|
02/28/2022 |
4
| Mow Jonathan P (CEO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 82,500 restricted stock units
@ $0 Granted 385,000 options to buy
@ $1.13, valued at
$435.1k
|
|
11/23/2021 |
4
| Mow Jonathan P (CEO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 5,623 shares
@ $2.01, valued at
$11.3k
|
|
11/23/2021 |
4
| Arnold Susan Elizabeth (SVP, Technical Operations) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 2,559 shares
@ $2.01, valued at
$5.1k
|
|
11/23/2021 |
4
| Sharp John P (CFO) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 2,017 shares
@ $2.01, valued at
$4.1k
|
|
11/23/2021 |
4
| Hanson Kristopher (VP, Head of Legal) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 1,545 shares
@ $2.01, valued at
$3.1k
|
|
11/23/2021 |
4
| Burkhardt Glen (VP, Human Resources) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 5,766 shares
@ $2.01, valued at
$11.6k
Sold 5,766 shares
@ $2.37, valued at
$13.7k
|
|
11/09/2021 |
4
| Birchall Jonathan (Chief Commercial Officer) has filed a Form 4 on PhaseBio Pharmaceuticals Inc
Txns:
| Granted 250,000 options to buy
@ $3.37, valued at
$842.5k
|
|
|
|
|